HFA
DNLI icon

Hoover Financial Advisors’s Denali Therapeutics DNLI Stock Holding History

Hoover Financial Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$16K Hold
200
– – ﹤0.01% 418
2021
Q1 		$11K Hold
200
– – ﹤0.01% 414
2020
Q4 		$15K Buy
+200
New +$12.1K ﹤0.01% 366

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hoover Financial Advisors's DNLI Position: Q2 2021 in Review

Hoover Financial Advisors held its Denali Therapeutics (DNLI) position steady in Q2 2021 at 200 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

Hoover Financial Advisors first reported a position in DNLI in Q4 2020 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Hoover Financial Advisors held 200 shares of Denali Therapeutics worth $16K as of Q2 2021.
  • Hoover Financial Advisors left its Denali Therapeutics share count unchanged in Q2 2021.
  • Denali Therapeutics made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #418 holding.
  • Hoover Financial Advisors first reported a position in Denali Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.